What's Hot

View all perspectives
      RT @doctorRBC: ⭐️AxSpA pts with decrease in oral microbial diversity
      ⭐️Immune response to oral/fecal microbes al

      Robert B Chao, MD doctorRBC

      3 years 2 months ago
      ⭐️AxSpA pts with decrease in oral microbial diversity ⭐️Immune response to oral/fecal microbes altered in AxSpA pts. ⭐️HLA-B27 associated ⬆️IgA coated microbes, may contribute to development of AxSpA Abs#0052 https://t.co/NQgm0lpYJj #ACR21 @RheumNow
      RT @RichardPAConway: Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare mo

      Richard Conway RichardPAConway

      3 years 2 months ago
      Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare more patients biopsy? Abstr#0001 #ACR21 @RheumNow https://t.co/ikNXCEOeuj
      RT @RichardPAConway: Meta-analysis from @rheum_covid with @HsiehEvelyn shows that people with rheumatic disease are atâ¬

      Richard Conway RichardPAConway

      3 years 2 months ago
      Meta-analysis from @rheum_covid with @HsiehEvelyn shows that people with rheumatic disease are at⬆️risk of SARS-CoV-2 infection and⬆️mortality from COVID-19. Abstr#0086 #ACR21 @RheumNow #ACRBest https://t.co/B7tWs02gfc
      RT @RichardPAConway: Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Mos

      Richard Conway RichardPAConway

      3 years 2 months ago
      Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Most MPO+, but also rarely seen with PR3+. 47% ⬆️ risk of death. Abstr#0430 #ACR21 @RheumNow https://t.co/6MnxqW92bz
      RT @RichardPAConway: Completely new one for me, Dr Taniguchi presenting on using ear ultrasound to diagnose and monitor

      Richard Conway RichardPAConway

      3 years 2 months ago
      Completely new one for me, Dr Taniguchi presenting on using ear ultrasound to diagnose and monitor disease activity in relapsing polychondritis. Appears useful, I suspect in clinical practice more so for diagnosis. Abstr#0169 #ACR21 @RheumNow https://t.co/PLJtkYkP3A
      RT @RichardPAConway: Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆ï¸

      Richard Conway RichardPAConway

      3 years 2 months ago
      Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi
      RT @RichardPAConway: Dr McDermott @jeffsparks on risk factors for RA-bronchiectasis. Seropositivity, older age at RA ons

      Richard Conway RichardPAConway

      3 years 2 months ago
      Dr McDermott @jeffsparks on risk factors for RA-bronchiectasis. Seropositivity, older age at RA onset, and lower BMI⬆️risk. Abstr#0288 #ACR21 @RheumNow https://t.co/7d2ZVWLzn6
      RT @RichardPAConway: Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think

      Richard Conway RichardPAConway

      3 years 2 months ago
      Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ
      RT @RichardPAConway: Dr Adachi presents ⬆️BMD gain with denosumab than risedronate in RA. Non-significant reduction

      Richard Conway RichardPAConway

      3 years 2 months ago
      Dr Adachi presents ⬆️BMD gain with denosumab than risedronate in RA. Non-significant reduction in fractures (very small numbers) Interesting, but need to see fracture benefit in larger study to justify dmab as first line Abstr#0445 #ACR21 @RheumNow https://t.co/GgaS9JZGzb
      RT @RichardPAConway: Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need co

      Richard Conway RichardPAConway

      3 years 2 months ago
      Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
      RT @drdavidliew: Diabetes puts you at risk of cardiovascular disease, right?
      What about RA?
      Look at this graph and compa

      David Liew drdavidliew

      3 years 2 months ago
      Diabetes puts you at risk of cardiovascular disease, right? What about RA? Look at this graph and compare the pair. "already it was impossible to say which was which” - George Orwell, Animal Farm #ACR21 ABST0287 @RheumNow https://t.co/r0yaeC530l https://t.co/mKJhoyJ2Cn
      RT @_Castillo_Pedro: Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to I

      Pedro Castillo _Castillo_Pedro

      3 years 2 months ago
      Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to IFX or switched from IFX: 💠IFX-naive: improved disease activity 💠IFX-switched: maintained stable disease 💠No new safety concerns https://t.co/VGBicnq15w #ACR21 Abst#0817 @RheumNow
      RT @_Castillo_Pedro: Small but important study of LN Class III, IV, and/or V with 6/18 pts considered complete responder

      Pedro Castillo _Castillo_Pedro

      3 years 2 months ago
      Small but important study of LN Class III, IV, and/or V with 6/18 pts considered complete responders by UProt (<500mg/g) continued to⬇️in renal fxn over 5 yrs. Bottom line: even dramatic ⬇️UProt does not tell the whole story. https://t.co/51x4DlXkJC #ACR21 Abst#1284 @RheumNow
      RT @_Castillo_Pedro: Infxn risk of 1st year on rituximab for mod to severe SLE vs standard-of-care
      🔹Most common SoC R

      Pedro Castillo _Castillo_Pedro

      3 years 2 months ago
      Infxn risk of 1st year on rituximab for mod to severe SLE vs standard-of-care 🔹Most common SoC Rx: MMF, Aza, and/or cyclophosphamide 🔹🚫significant diff 🔹RTX pts = ⬆️dz duration, ⬆️# of prior meds, ⬇️maintenance steroid dose https://t.co/AYQFXqlubl #ACR21 Abst1288 @RheumNow
      RT @_Castillo_Pedro: SLE: Belimumab + standard rx significantly⬇️risk of severe flares vs placebo.
      Greatest in those

      Pedro Castillo _Castillo_Pedro

      3 years 2 months ago
      SLE: Belimumab + standard rx significantly⬇️risk of severe flares vs placebo. Greatest in those with: 🔹+dsDNA 🔹low C3 or C4 🔹SLICC/ACR Damage index of 0 (argument for early treatment!) https://t.co/UcGXEklqwJ #ACR21 Abst#1295 @RheumNow

      Podcasts

      • Alive In 2025 (1.10.2025)
      • VITAL Info On Autoimmune Disease (2.9.2024)
      • Bah Humbug Vitamin D (12.20.2024)

      Catch up on Conference Podcasts

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright 2024 All Rights Reserved.

      ×